[1]
Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, Westermark P, Nomenclature Committee of the International Society of Amyloidosis. Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis. 2012 Dec:19(4):167-70. doi: 10.3109/13506129.2012.734345. Epub 2012 Nov 1
[PubMed PMID: 23113696]
[2]
Dammacco R, Merlini G, Lisch W, Kivelä TT, Giancipoli E, Vacca A, Dammacco F. Amyloidosis and Ocular Involvement: an Overview. Seminars in ophthalmology. 2020 Jan 2:35(1):7-26. doi: 10.1080/08820538.2019.1687738. Epub 2019 Dec 12
[PubMed PMID: 31829761]
Level 3 (low-level) evidence
[3]
Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, Hawkins PN. Natural history and outcome in systemic AA amyloidosis. The New England journal of medicine. 2007 Jun 7:356(23):2361-71
[PubMed PMID: 17554117]
[5]
Reynolds MM, Veverka KK, Gertz MA, Dispenzieri A, Zeldenrust SR, Leung N, Pulido JS. OCULAR MANIFESTATIONS OF SYSTEMIC AMYLOIDOSIS. Retina (Philadelphia, Pa.). 2018 Jul:38(7):1371-1376. doi: 10.1097/IAE.0000000000001901. Epub
[PubMed PMID: 29068915]
[6]
Minnella AM, Rissotto R, Antoniazzi E, Di Girolamo M, Luigetti M, Maceroni M, Bacherini D, Falsini B, Rizzo S, Obici L. Ocular Involvement in Hereditary Amyloidosis. Genes. 2021 Jun 22:12(7):. doi: 10.3390/genes12070955. Epub 2021 Jun 22
[PubMed PMID: 34206500]
[7]
Banerjee P, Alam MS, Subramanian N, Kundu D, Koka K, Poonam NS, Mukherjee B. Orbital and adnexal amyloidosis: Thirty years experience at a tertiary eye care center. Indian journal of ophthalmology. 2021 May:69(5):1161-1166. doi: 10.4103/ijo.IJO_2528_20. Epub
[PubMed PMID: 33913851]
[8]
Ikura H, Endo J, Kitakata H, Moriyama H, Sano M, Fukuda K. Molecular Mechanism of Pathogenesis and Treatment Strategies for AL Amyloidosis. International journal of molecular sciences. 2022 Jun 6:23(11):. doi: 10.3390/ijms23116336. Epub 2022 Jun 6
[PubMed PMID: 35683015]
[9]
Singh RB, Singhal S, Sinha S, Cho J, Nguyen AX, Dhingra LS, Kaur S, Sharma V, Agarwal A. Ocular complications of plasma cell dyscrasias. European journal of ophthalmology. 2023 Sep:33(5):1786-1800. doi: 10.1177/11206721231155974. Epub 2023 Feb 9
[PubMed PMID: 36760117]
[10]
Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, Westermark P. Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis. 2014 Dec:21(4):221-4. doi: 10.3109/13506129.2014.964858. Epub 2014 Sep 29
[PubMed PMID: 25263598]
[11]
Murdoch IE, Sullivan TJ, Moseley I, Hawkins PN, Pepys MB, Tan SY, Garner A, Wright JE. Primary localised amyloidosis of the orbit. The British journal of ophthalmology. 1996 Dec:80(12):1083-6
[PubMed PMID: 9059275]
[12]
Jamshidi P, Levi J, Suarez MJ, Rivera R, Mahoney N, Eberhart CG, Rosenberg A, Rodriguez FJ. Clinicopathologic and Proteomic Analysis of Amyloidomas Involving the Ocular Surface and Adnexa. American journal of clinical pathology. 2022 Apr 1:157(4):620-627. doi: 10.1093/ajcp/aqab161. Epub
[PubMed PMID: 34698334]
[13]
Taban M, Piva A, See RF, Sadun AA, Quiros PA. Review: orbital amyloidosis. Ophthalmic plastic and reconstructive surgery. 2004 Mar:20(2):162-5
[PubMed PMID: 15083087]
[14]
Segado Martínez M, Ruiz García G, Abenza Baeza S. Amyloidosis localized in lacrimal gland. Medicina clinica. 2022 Aug 12:159(3):e23-e24. doi: 10.1016/j.medcli.2022.02.027. Epub 2022 May 25
[PubMed PMID: 35643772]
[15]
Neri A, Rubino P, Macaluso C, Gandolfi SA. Light-chain amyloidosis mimicking giant cell arteritis in a bilateral anterior ischemic optic neuropathy case. BMC ophthalmology. 2013 Dec 20:13():82. doi: 10.1186/1471-2415-13-82. Epub 2013 Dec 20
[PubMed PMID: 24359546]
Level 3 (low-level) evidence
[16]
Suesskind D, Ziemssen F, Rohrbach JM. Conjunctival amyloidosis -- clinical and histopathologic features. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2015 Aug:253(8):1377-83. doi: 10.1007/s00417-015-2932-3. Epub 2015 Jan 27
[PubMed PMID: 25619666]
[17]
Carrwik C, Stenevi U. Lattice corneal dystrophy, gelsolin type (Meretoja's syndrome). Acta ophthalmologica. 2009 Nov:87(8):813-9. doi: 10.1111/j.1755-3768.2009.01686.x. Epub
[PubMed PMID: 19832730]
[18]
Kaza H, Barik MR, Reddy MM, Mittal R, Das S. Gelatinous drop-like corneal dystrophy: a review. The British journal of ophthalmology. 2017 Jan:101(1):10-15. doi: 10.1136/bjophthalmol-2016-309555. Epub 2016 Dec 2
[PubMed PMID: 27913443]
[19]
Milovanova E, Gomon S, Rocha G. Classic lattice corneal dystrophy: a brief review and summary of treatment modalities. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2023 Nov 7:():. doi: 10.1007/s00417-023-06297-6. Epub 2023 Nov 7
[PubMed PMID: 37934291]
[20]
Maramattom BV, Chickabasaviah YT. A new Indian family affected by gelsolin amyloidosis. Neurology India. 2013 Nov-Dec:61(6):673-5. doi: 10.4103/0028-3886.125372. Epub
[PubMed PMID: 24441349]
[21]
Casal I, Monteiro S, Abreu C, Neves M, Oliveira L, Beirão M. Meretoja's Syndrome: Lattice Corneal Dystrophy, Gelsolin Type. Case reports in medicine. 2017:2017():2843417. doi: 10.1155/2017/2843417. Epub 2017 Jan 31
[PubMed PMID: 28250773]
[22]
Adams D, Ando Y, Beirão JM, Coelho T, Gertz MA, Gillmore JD, Hawkins PN, Lousada I, Suhr OB, Merlini G. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. Journal of neurology. 2021 Jun:268(6):2109-2122. doi: 10.1007/s00415-019-09688-0. Epub 2020 Jan 6
[PubMed PMID: 31907599]
Level 3 (low-level) evidence
[23]
Venkatesh P, Selvan H, Singh SB, Gupta D, Kashyap S, Temkar S, Gogia V, Tripathy K, Chawla R, Vohra R. Vitreous Amyloidosis: Ocular, Systemic, and Genetic Insights. Ophthalmology. 2017 Jul:124(7):1014-1022. doi: 10.1016/j.ophtha.2017.03.011. Epub 2017 Apr 12
[PubMed PMID: 28412068]
[24]
Li Z, Du K, Chu X, Lv H, Zhang W, Wang Z, Yuan Y, Meng L. TTR Gly83Arg Mutation: Beyond Familial Vitreous Amyloidosis. Frontiers in neurology. 2021:12():821003. doi: 10.3389/fneur.2021.821003. Epub 2022 Feb 3
[PubMed PMID: 35185758]
[25]
Pathak-Ray V, Pulpa V, Blyth C. Vitreous amyloidosis and secondary glaucoma-a case report. Eye (London, England). 2002 Jul:16(4):492-4
[PubMed PMID: 12101461]
Level 3 (low-level) evidence
[26]
Mano F, Dispenzieri A, Kusaka S, Pavesio C, Khalid H, Keane PA, Pulido JS. ASSOCIATION BETWEEN CHOROIDAL CHARACTERISTICS AND SYSTEMIC SEVERITY IN AMYLOIDOSIS. Retina (Philadelphia, Pa.). 2021 May 1:41(5):1037-1046. doi: 10.1097/IAE.0000000000002961. Epub
[PubMed PMID: 32826787]
[27]
Mora-Horna ER, Rojas-Padilla R, López VG, Guzmán MJ, Ceriotto A, Salcedo G. Ocular adnexal and orbital amyloidosis: a case series and literature review. International ophthalmology. 2016 Apr:36(2):281-98. doi: 10.1007/s10792-015-0138-7. Epub 2015 Oct 14
[PubMed PMID: 26466598]
Level 2 (mid-level) evidence
[28]
Leibovitch I, Selva D, Goldberg RA, Sullivan TJ, Saeed P, Davis G, McCann JD, McNab A, Rootman J. Periocular and orbital amyloidosis: clinical characteristics, management, and outcome. Ophthalmology. 2006 Sep:113(9):1657-64
[PubMed PMID: 16828514]
[29]
Hamidi Asl K, Liepnieks JJ, Nunery WR, Yazaki M, Benson MD. Kappa III immunoglobulin light chain origin of localized orbital amyloidosis. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis. 2004 Sep:11(3):179-83
[PubMed PMID: 15523920]
[30]
Yerli H, Aydin E, Avci S, Haberal N, Oto S. Focal Amyloidosis of the Orbit Presenting as a Mass: MRI and CT Features. Iranian journal of radiology : a quarterly journal published by the Iranian Radiological Society. 2011 Dec:8(4):241-4. doi: 10.5812/iranjradiol.4555. Epub 2011 Dec 25
[PubMed PMID: 23329948]
[31]
Menetti F, Bartolomei I, Ambrosini-Spaltro A, Salvi F, Agati R, Leonardi M. Amyloidoma Involving the Orbit, Meckel's Cave and Infratemporal Fossa: 3T MRI Findings. The neuroradiology journal. 2009 Mar 23:22(1):41-7
[PubMed PMID: 24206952]
[32]
Kakihara S, Hirano T, Kitahara J, Matsuda Y, Imai A, Miyahara T, Murata T. OCULAR ANGIOGRAPHIC FEATURES IN JAPANESE PATIENTS WITH VAL30MET HEREDITARY TRANSTHYRETIN AMYLOIDOSIS. Retina (Philadelphia, Pa.). 2022 Jan 1:42(1):210-215. doi: 10.1097/IAE.0000000000003291. Epub
[PubMed PMID: 34483312]
[33]
Kakihara S, Hirano T, Matsuda Y, Takano D, Imai A, Miyahara T, Murata T. Deposits on Retinal Surface Seen on OCT in Ocular Amyloidosis. Ophthalmology. Retina. 2021 Oct:5(10):1005-1008. doi: 10.1016/j.oret.2020.12.028. Epub 2021 Jan 7
[PubMed PMID: 33422693]
[34]
Fraunfelder FW. Liquid nitrogen cryotherapy for conjunctival amyloidosis. Archives of ophthalmology (Chicago, Ill. : 1960). 2009 May:127(5):645-8. doi: 10.1001/archophthalmol.2008.535. Epub
[PubMed PMID: 19433714]
[35]
Asao C, Korogi Y, Hotta A, Shimomura O, Kitajima M, Negi A, Takahashi M. Orbital pseudotumors: value of short inversion time inversion-recovery MR imaging. Radiology. 1997 Jan:202(1):55-9
[PubMed PMID: 8988192]
[36]
Simon EM, Zoarski GH, Rothman MI, Numaguchi Y, Zagardo MT, Mathis JM. Systemic sarcoidosis with bilateral orbital involvement: MR findings. AJNR. American journal of neuroradiology. 1998 Feb:19(2):336-7
[PubMed PMID: 9504490]
[37]
Thorn-Kany M, Arrué P, Delisle MB, Lacroix F, Lagarrigue J, Manelfe C. Cavernous hemangiomas of the orbit: MR imaging. Journal of neuroradiology = Journal de neuroradiologie. 1999 Jun:26(2):79-86
[PubMed PMID: 10444931]
[38]
Klintworth GK. Corneal dystrophies. Orphanet journal of rare diseases. 2009 Feb 23:4():7. doi: 10.1186/1750-1172-4-7. Epub 2009 Feb 23
[PubMed PMID: 19236704]
[39]
Touhami S, Leclercq M, Stanescu-Segall D, Touitou V, Bodaghi B. Differential Diagnosis of Vitritis in Adult Patients. Ocular immunology and inflammation. 2021 May 19:29(4):786-795. doi: 10.1080/09273948.2021.1898001. Epub 2021 May 18
[PubMed PMID: 34003716]
[40]
Prager AJ, Habib LA, Gambogi T, Busam KJ, Marr BP. Long-Term Follow-Up of 4 Patients with Conjunctival Amyloidosis. Ocular oncology and pathology. 2018 Sep:4(5):313-317. doi: 10.1159/000485918. Epub 2018 Feb 13
[PubMed PMID: 30320104]
[41]
Eneh AA, Farmer J, Kratky V. Primary localized orbital amyloid: case report and literature review; 2004-2015. Canadian journal of ophthalmology. Journal canadien d'ophtalmologie. 2016 Aug:51(4):e131-e136. doi: 10.1016/j.jcjo.2016.03.019. Epub 2016 Jul 1
[PubMed PMID: 27521683]
Level 3 (low-level) evidence
[42]
Ono T, Ishiyama S, Hayashidera T, Mori Y, Nejima R, Miyata K, Amano S. Twelve-year follow-up of penetrating keratoplasty. Japanese journal of ophthalmology. 2017 Mar:61(2):131-136. doi: 10.1007/s10384-016-0489-2. Epub 2016 Nov 24
[PubMed PMID: 27885526]
[43]
Palladini G, Merlini G. Current treatment of AL amyloidosis. Haematologica. 2009 Aug:94(8):1044-8. doi: 10.3324/haematol.2009.008912. Epub
[PubMed PMID: 19644136]